Polygenic Risk Modelling for Prediction of Epithelial Ovarian Cancer Risk
![Loading Loading](https://www.medrxiv.org/sites/all/modules/contrib/panels_ajax_tab/images/loading.gif)
Abstract
Polygenic risk scores (PRS) for epithelial ovarian cancer (EOC) have the potential to improve risk stratification. Joint estimation of Single Nucleotide Polymorphism (SNP) effects in models could improve predictive performance over standard approaches of PRS construction. Here, we implemented computationally-efficient, penalized, logistic regression models (lasso, elastic net, stepwise) to individual level genotype data and a Bayesian framework with continuous shrinkage, “select and shrink for summary statistics” (S4), to summary level data for epithelial non-mucinous ovarian cancer risk prediction. We developed the models in a dataset consisting of 23,564 non-mucinous EOC cases and 40,138 controls participating in the Ovarian Cancer Association Consortium (OCAC) and validated the best models in three populations of different ancestries: prospective data from 198,101 women of European ancestry; 7,669 women of East Asian ancestry; 1,072 women of African ancestry, and in 18,915 BRCA1 and 12,337 BRCA2 pathogenic variant carriers of European ancestry. In the external validation data, the model with the strongest association for non-mucinous EOC risk derived from the OCAC model development data was the S4 model (27,240 SNPs) with odds ratios (OR) of 1.38(95%CI:1.28–1.48,AUC:0.588) per unit standard deviation, in women of European ancestry; 1.14(95%CI:1.08–1.19,AUC:0.538) in women of East Asian ancestry; 1.38(95%CI:1.21-1.58,AUC:0.593) in women of African ancestry; hazard ratios of 1.37(95%CI:1.30–1.44,AUC:0.592) in BRCA1 pathogenic variant carriers and 1.51(95%CI:1.36-1.67,AUC:0.624) in BRCA2 pathogenic variant carriers. Incorporation of the S4 PRS in risk prediction models for ovarian cancer may have clinical utility in ovarian cancer prevention programs.
Competing Interest Statement
Anna DeFazio has received a research grant from AstraZeneca, not directly related to the content of this manuscript. The other authors declare no conflicts of interest. Matthias W. Beckmann conducts research funded by Amgen, Novartis and Pfizer. Peter A. Fashing conducts research funded by Amgen, Novartis and Pfizer. He received Honoraria from Roche, Novartis and Pfizer.
Funding Statement
All funding support are reported in the Supplementary Material
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
All study participants provided written informed consent and participated in research or clinical studies at the host institute under ethically approved protocols. The studies and their approving institutes are listed as a separate online Supplement (Ethics Statement)
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All data are publicly available
Subject Area
- Addiction Medicine (336)
- Allergy and Immunology (664)
- Anesthesia (178)
- Cardiovascular Medicine (2600)
- Dermatology (218)
- Emergency Medicine (391)
- Epidemiology (12139)
- Forensic Medicine (10)
- Gastroenterology (752)
- Genetic and Genomic Medicine (4035)
- Geriatric Medicine (380)
- Health Economics (671)
- Health Informatics (2607)
- Health Policy (995)
- Hematology (359)
- HIV/AIDS (833)
- Medical Education (397)
- Medical Ethics (109)
- Nephrology (426)
- Neurology (3804)
- Nursing (208)
- Nutrition (567)
- Oncology (1991)
- Ophthalmology (578)
- Orthopedics (235)
- Otolaryngology (303)
- Pain Medicine (250)
- Palliative Medicine (73)
- Pathology (470)
- Pediatrics (1100)
- Primary Care Research (443)
- Public and Global Health (6473)
- Radiology and Imaging (1379)
- Respiratory Medicine (866)
- Rheumatology (395)
- Sports Medicine (337)
- Surgery (438)
- Toxicology (52)
- Transplantation (185)
- Urology (165)